400 related articles for article (PubMed ID: 35887186)
1. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy.
Lee JY; Kannan B; Lim BY; Li Z; Lim AH; Loh JW; Ko TK; Ng CC; Chan JY
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887186
[TBL] [Abstract][Full Text] [Related]
2. Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery.
Bai Z; Su G; Fan R
Genomics Proteomics Bioinformatics; 2021 Apr; 19(2):191-207. PubMed ID: 34000441
[TBL] [Abstract][Full Text] [Related]
3. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
4. Multi-Omics Profiling of the Tumor Microenvironment.
Van Oekelen O; Laganà A
Adv Exp Med Biol; 2022; 1361():283-326. PubMed ID: 35230695
[TBL] [Abstract][Full Text] [Related]
5. Understanding the tumor microenvironment for effective immunotherapy.
Sadeghi Rad H; Monkman J; Warkiani ME; Ladwa R; O'Byrne K; Rezaei N; Kulasinghe A
Med Res Rev; 2021 May; 41(3):1474-1498. PubMed ID: 33277742
[TBL] [Abstract][Full Text] [Related]
6. The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.
Sadeghi Rad H; Bazaz SR; Monkman J; Ebrahimi Warkiani M; Rezaei N; O'Byrne K; Kulasinghe A
Clin Transl Immunology; 2020; 9(11):e1215. PubMed ID: 33251010
[TBL] [Abstract][Full Text] [Related]
7. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Li X; Shao C; Shi Y; Han W
J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
[TBL] [Abstract][Full Text] [Related]
9. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
Wang Y; Johnson KCC; Gatti-Mays ME; Li Z
J Hematol Oncol; 2022 Aug; 15(1):118. PubMed ID: 36031601
[TBL] [Abstract][Full Text] [Related]
10.
Li M; Ma Y; Zhong Y; Liu Q; Chen C; Qiang L; Wang X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037113
[TBL] [Abstract][Full Text] [Related]
11. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Hu-Lieskovan S; Bhaumik S; Dhodapkar K; Grivel JJB; Gupta S; Hanks BA; Janetzki S; Kleen TO; Koguchi Y; Lund AW; Maccalli C; Mahnke YD; Novosiadly RD; Selvan SR; Sims T; Zhao Y; Maecker HT
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33268350
[TBL] [Abstract][Full Text] [Related]
12. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
Peng M
Front Immunol; 2022; 13():970885. PubMed ID: 36003383
[TBL] [Abstract][Full Text] [Related]
13. Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies.
Augustin RC; Cai WL; Luke JJ; Bao R
Clin Cancer Res; 2024 May; 30(9):1724-1732. PubMed ID: 38236069
[TBL] [Abstract][Full Text] [Related]
14. Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity.
Sorin M; Karimi E; Rezanejad M; Yu MW; Desharnais L; McDowell SAC; Doré S; Arabzadeh A; Breton V; Fiset B; Wei Y; Rayes R; Orain M; Coulombe F; Manem VSK; Gagne A; Quail DF; Joubert P; Spicer JD; Walsh LA
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36725085
[TBL] [Abstract][Full Text] [Related]
15. Assay-agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple-negative breast cancer.
Ziegler C; Mir A; Anandakrishnan S; Martin P; Contreras E; Slemons I; Witkowski B; DeSilva C; Farmer A; Vranic S; Gatalica Z; Richardson D; Derkach DN
Mol Oncol; 2023 Oct; 17(10):1953-1961. PubMed ID: 37666492
[TBL] [Abstract][Full Text] [Related]
16. Applications of Single-Cell Omics in Tumor Immunology.
Liu J; Qu S; Zhang T; Gao Y; Shi H; Song K; Chen W; Yin W
Front Immunol; 2021; 12():697412. PubMed ID: 34177965
[TBL] [Abstract][Full Text] [Related]
17. Recent advancements in tumour microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis.
Andhari MD; Antoranz A; De Smet F; Bosisio FM
Int Rev Cell Mol Biol; 2024; 382():207-237. PubMed ID: 38225104
[TBL] [Abstract][Full Text] [Related]
18. Applications of Single-Cell Omics to Dissect Tumor Microenvironment.
Guo T; Li W; Cai X
Front Genet; 2020; 11():548719. PubMed ID: 33329692
[TBL] [Abstract][Full Text] [Related]
19. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.
Sivapalan L; Murray JC; Canzoniero JV; Landon B; Jackson J; Scott S; Lam V; Levy BP; Sausen M; Anagnostou V
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
